Healthcare company Tevogen Bio revealed on Wednesday that it has filed its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to develop a COVID-19 treatment using proprietary antigen specific T cell technology.
In partnership with Dr Neal Flomenberg, a renowned bone marrow transplant expert and chair of the Department of Medical Oncology at Thomas Jefferson University, the company plans to evaluate T cell technology to treat hospitalized COVID-19 patients.
Utilising Tevogen's proprietary immunotherapy platform and Dr Flomenberg's expertise in research and the transplantation of T cells, the partnership will conduct clinical trials of T cell treatments for COVID-19. The T cells will be generated in the laboratory and administered to the very ill Corona patients. The body generates specific T cells to rid itself of viruses including COVID-19 in normal circumstances.
Additionally, Yale-trained infectious disease epidemiologist Dr Ryan Saadi is leading the company's efforts to develop a COVID-19 curative treatment.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial